BioAge Labs, Inc.
BIOA
Analytical Summary
BioAge Labs, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.
4-Year Financial Trajectory
AnnualBullish Indicators
- Debt to EquityDebt to Equity is in the top quartile (lower is better)
Bearish Risks
- Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
66.2%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
82.6%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-13.4%
Weak
Weak
Year-over-year change in net income |
-11.4%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
52.6%
Excellent
Excellent
Year-over-year change in free cash flow |
78.4%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
→
Excellent
Stable
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| FCF / Net Income (x) |
1.02x
Fair
↑
Fair
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.73x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.59x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-34.1%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-24.0%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
29.3%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-31.5%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-21.8%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-186.7%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-29.6%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-298%)
|
-22.0%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-247%)
|
36.8%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+146%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) |
0.00x
Excellent
↑
Excellent
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
0.01x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-99%)
|
-0.05x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-108%)
|
— |
| Interest Coverage (x) |
-151.85x
Weak
↓
Weak
Declining
Operating income divided by interest expense
Optimal:
> 5x
|
-55.07x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
-41.90x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
| Net Debt (USD) | $-188.89M | $-351.85M | $-13.44M | — |
| Debt / EBITDA (x) |
0.00x
Excellent
↑
Excellent
Improving
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
-0.03x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
-0.17x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $8.99M | $0.00 | — | — |
| Depreciation Expense (USD) | $200.00K | $200.00K | $200.00K | — |
| Net Income, GAAP (USD) | $-80.61M | $-71.11M | $-63.85M | — |
| Operating Cash Flow (USD) | $-81.63M | $-51.52M | $-37.36M | — |
Secondary lens
Benchmark Lens
Compare BIOA against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare BIOA against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for BIOA
Debt to Equity is in the top quartile (lower is better)
Return on Common Equity (%) is in the bottom quartile
Percentile Rankings
How BIOA compares to all companies
Peer Comparison
BIOA vs similar peers
Compare BIOA with peers
Stack BIOA against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters